X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2980) 2980
Publication (178) 178
Book Review (35) 35
Book Chapter (24) 24
Dissertation (8) 8
Conference Proceeding (7) 7
Magazine Article (4) 4
Web Resource (3) 3
Book / eBook (1) 1
Data Set (1) 1
Newspaper Article (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2053) 2053
index medicus (1632) 1632
mucositis (1571) 1571
male (1382) 1382
chemotherapy (1328) 1328
female (1304) 1304
oncology (1246) 1246
cancer (1043) 1043
middle aged (976) 976
adult (844) 844
oral mucositis (800) 800
aged (741) 741
radiotherapy (615) 615
animals (547) 547
care and treatment (524) 524
antineoplastic agents - adverse effects (477) 477
prevention (454) 454
mucositis - chemically induced (439) 439
treatment outcome (438) 438
therapy (437) 437
stomatitis (393) 393
stomatitis - etiology (378) 378
adolescent (337) 337
toxicity (332) 332
medicine & public health (329) 329
analysis (328) 328
patients (319) 319
stomatitis - chemically induced (318) 318
hematology (311) 311
health aspects (307) 307
dentistry, oral surgery & medicine (297) 297
pharmacology & pharmacy (294) 294
stomatitis - prevention & control (294) 294
research (292) 292
radiation (290) 290
stomatitis - drug therapy (288) 288
head and neck neoplasms - radiotherapy (286) 286
mucositis - etiology (275) 275
head (274) 274
risk factors (271) 271
radiation therapy (270) 270
transplantation (270) 270
dentistry (264) 264
cancer therapies (262) 262
neoplasms - drug therapy (261) 261
head and neck cancer (259) 259
antineoplastic combined chemotherapy protocols - adverse effects (241) 241
management (239) 239
child (236) 236
nursing (231) 231
health care sciences & services (228) 228
rats (219) 219
inflammation (216) 216
mice (216) 216
aged, 80 and over (213) 213
antineoplastic combined chemotherapy protocols - therapeutic use (211) 211
clinical trials (211) 211
quality of life (210) 210
pain (209) 209
rehabilitation (205) 205
neck-cancer (204) 204
young adult (200) 200
mucositis - drug therapy (198) 198
radiotherapy - adverse effects (198) 198
double-blind (196) 196
5-fluorouracil (195) 195
complications and side effects (193) 193
prospective studies (193) 193
retrospective studies (191) 191
stem cells (184) 184
surgery (183) 183
antineoplastic agents - therapeutic use (182) 182
drug therapy (182) 182
diarrhea (172) 172
hematology, oncology and palliative medicine (169) 169
immunology (169) 169
methotrexate (167) 167
double-blind method (164) 164
fluorouracil (164) 164
mouth mucosa - drug effects (163) 163
children (162) 162
side effects (162) 162
stem-cell transplantation (162) 162
radiology, nuclear medicine & medical imaging (160) 160
bone-marrow-transplantation (159) 159
head and neck neoplasms - drug therapy (156) 156
fluorouracil - adverse effects (154) 154
induced oral mucositis (154) 154
medicine (154) 154
radiation-therapy (154) 154
cancer patients (153) 153
severity of illness index (153) 153
pain medicine (150) 150
child, preschool (147) 147
trial (147) 147
dose-response relationship, drug (146) 146
pediatrics (146) 146
dosage and administration (143) 143
rehabilitation medicine (142) 142
combined modality therapy (140) 140
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2921) 2921
Japanese (38) 38
German (23) 23
French (16) 16
Chinese (13) 13
Portuguese (9) 9
Russian (9) 9
Polish (6) 6
Spanish (5) 5
Korean (4) 4
Dutch (3) 3
Italian (3) 3
Serbian (2) 2
Croatian (1) 1
Czech (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 203 - 218
There has been a rapid emergence of numerous targeted agents in the oncology community in the last decade. This exciting paradigm shift in drug development... 
Vandetanib | Panitumumab | Multikinase inhibitors | Bevacizumab | Macular eruption | Pigment changes | Paronychia | Supportive oncodermatology | Drug eruption | Sunitinib | Lapatinib | Cetuximab | Gefitinib | Vascular endothelial growth factor | Pazopanib | Dasatinib | Photosensitivity | Imatinib | Mucositis | Morbilliform | Chemotherapy | Side effects | Stomatitis | Alopecia | Disturbed wound healing | Erlotinib | Sorafenib | KIT | Monoclonal antibodies | Dry skin | Nilotinib | Drug rash | Targeted therapy | erbB receptor | Toxic erythema | Papulopustular eruption | Hyperkeratotic handefoot skin reaction | Antiangiogenic agents | Platelet-derived growth factor receptor | Ranibizumab | Small molecule | Cutaneous adverse effects | Drug reaction | Epidermal growth factor receptor inhibitors | Mucocutaneous hemorrhage | Cancer treatment | Dermatologic toxicities | BCR-ABL | Xerosis | Canertinib | Tyrosine kinase inhibitors | Dual kinase inhibitors | Adverse sequelae | Genital rash | Anticancer | HER2 | cancer treatment | small molecule | sorafenib | morbilliform | photosensitivity | lapatinib | panitumumab | xerosis | chemotherapy | METASTATIC COLORECTAL-CANCER | mucocutaneous hemorrhage | canertinib | IMATINIB-INDUCED ERYTHRODERMA | bevacizumab | side effects | drug reaction | FOOT SKIN REACTION | sunitinib | papulopustular eruption | cetuximab | imatinib | gefitinib | drug rash | alopecia | EPIDERMAL-GROWTH-FACTOR | dry skin | disturbed wound healing | ADVANCED HEPATOCELLULAR-CARCINOMA | CHRONIC MYELOGENOUS LEUKEMIA | pigment changes | paronychia | stomatitis | dual kinase inhibitors | cutaneous adverse effects | anticancer | ranibizumab | epidermal growth factor receptor inhibitors | DERMATOLOGY | hyperkeratotic hand-foot skin reaction | tyrosine kinase inhibitors | antiangiogenic agents | dermatologic toxicities | drug eruption | multikinase inhibitors | dasatinib | nilotinib | platelet-derived growth factor receptor | adverse sequelae | supportive oncodermatology | targeted therapy | genital rash | FACTOR RECEPTOR INHIBITORS | macular eruption | toxic erythema | erlotinib | pazopanib | CHRONIC MYELOID-LEUKEMIA | EYELASH TRICHOMEGALY SECONDARY | mucositis | vandetanib | vascular endothelial growth factor | PLACEBO-CONTROLLED TRIAL | monoclonal antibodies | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Humans | Drug Eruptions - therapy | Mucositis - chemically induced | Dose-Response Relationship, Drug | Dermatitis, Photoallergic - etiology | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug Eruptions - diagnosis | Fusion Proteins, bcr-abl - antagonists & inhibitors | Hair Diseases - chemically induced | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Alopecia - chemically induced | Angiogenesis Inhibitors - adverse effects | Cell Membrane - drug effects | Index Medicus
Journal Article
Journal of Periodontology, ISSN 0022-3492, 05/2008, Volume 79, Issue 5, pp. 836 - 844
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2590 - 2597
Purpose Controversy exists regarding whether or not amifostine might reduce the efficacy of cancer treatment. The aim of this meta-analysis was to evaluate the... 
CELL LUNG-CANCER | INDUCED RECTAL TOXICITY | MODULATED RADIATION-THERAPY | INTRAVENOUS AMIFOSTINE | INDUCED MUCOSITIS | RANDOMIZED PHASE-III | FRACTIONATED RADIOTHERAPY | ACCELERATED RADIOTHERAPY | FOLLOW-UP | UMCG Approved | NECK-CANCER | ONCOLOGY | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Carcinoma - mortality | Lung Neoplasms - radiotherapy | Male | Radiotherapy - adverse effects | Treatment Failure | Adult | Female | Neoplasms - radiotherapy | Uterine Cervical Neoplasms - mortality | Carcinoma - drug therapy | Randomized Controlled Trials as Topic - statistics & numerical data | Uterine Cervical Neoplasms - radiotherapy | Head and Neck Neoplasms - drug therapy | Neoplasms - mortality | Uterine Cervical Neoplasms - drug therapy | Combined Modality Therapy | Carcinoma - radiotherapy | Carcinoma, Non-Small-Cell Lung - mortality | Neoplasms - drug therapy | Radiation Injuries - etiology | Disease-Free Survival | Head and Neck Neoplasms - radiotherapy | Radiation Injuries - prevention & control | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Radiation-Protective Agents - therapeutic use | Amifostine - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Head and Neck Neoplasms - mortality
Journal Article
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2016, Volume 24, Issue 6, pp. 2781 - 2792
Journal Article
Cancer, ISSN 0008-543X, 10/2003, Volume 98, Issue 7, pp. 1531 - 1539
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4740 - 4746
Purpose Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a... 
MAMMALIAN TARGET | TRIAL | THERAPY | GENE | ONCOLOGY | RAPAMYCIN INHIBITOR EVEROLIMUS | CYCLIN D1 | PATHWAY | C-MYC | RAD001 | MTOR | Lymphoma, Follicular - drug therapy | Humans | Intracellular Signaling Peptides and Proteins - drug effects | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Intracellular Signaling Peptides and Proteins - metabolism | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Protein-Serine-Threonine Kinases - metabolism | Sirolimus - adverse effects | Bone Marrow - drug effects | Lymphoma, Non-Hodgkin - drug therapy | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Chicago | Kaplan-Meier Estimate | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Remission Induction | Mucositis - chemically induced | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Lymphoma, Non-Hodgkin - metabolism | Protein-Serine-Threonine Kinases - drug effects | Aged | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Index Medicus | Original Reports | Hema13 | Hema15
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 2014, Volume 120, Issue 10, pp. 1453 - 1461
BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the... 
gastrointestinal | mucositis | guidelines | oral | stomatitis | Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) | HEAD | GASTROINTESTINAL MUCOSITIS | ISOO | CELL TRANSPLANTATION | RANDOMIZED-TRIAL | ZINC SUPPLEMENTATION | NECK-CANCER | ONCOLOGY | MUCOSAL INJURY | ORAL MUCOSITIS | DOUBLE-BLIND | LEVEL LASER THERAPY | Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC | Sucralfate - administration & dosage | Humans | Radiotherapy - adverse effects | Antineoplastic Agents - administration & dosage | Protective Agents - therapeutic use | Mucositis - prevention & control | Proctitis - prevention & control | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Neoplasms - radiotherapy | Intercellular Signaling Peptides and Proteins - administration & dosage | Low-Level Light Therapy | Esophagitis - therapy | Analgesics - therapeutic use | Proctitis - therapy | Anti-Infective Agents - therapeutic use | Evidence-Based Medicine | Mucositis - therapy | Cytokines - administration & dosage | Esophagitis - etiology | Stomatitis - etiology | Mucositis - chemically induced | Oral Hygiene | Anti-Ulcer Agents - administration & dosage | Neoplasms - drug therapy | Phototherapy | Stomatitis - therapy | Proctitis - etiology | Mucositis - etiology | Stomatitis - chemically induced | Esophagitis - prevention & control | Radiation-Protective Agents - therapeutic use | Stomatitis - prevention & control | Amifostine - therapeutic use | Cryotherapy | Hyperbaric Oxygenation | Practice guidelines (Medicine) | Usage | Care and treatment | Mucositis | Analysis | Cancer | Index Medicus | Abridged Index Medicus | Review
Journal Article